Frontlight ResearchEarly access
Trial site
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE
- 8running trials
- 6closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Conditions
- Lung cancer4 trials
- Metastatic breast cancer2 trials
- Acute lymphoblastic leukaemia1 trial
- Childhood cancers1 trial
- Chronic lymphocytic leukaemia1 trial
- Diffuse large B-cell lymphoma1 trial
- Gastric and oesophageal cancer1 trial
- Kidney cancer1 trial
- Melanoma1 trial
- Multiple myeloma1 trial
- Prostate cancer1 trial
- Phase
- Phase 39 trials
- Phase 23 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Completed6 trials
- Recruiting5 trials
- Active, not recruiting3 trials
- Lead sponsor
- Amgen4 trials
- Daiichi Sankyo2 trials
- Celgene1 trial
- Eisai Inc.1 trial
- Eli Lilly and Company1 trial
- and 5 more
Running trials
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
Active, not recruiting
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
Recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Chronic lymphocytic leukaemia1 recruiting
- Diffuse large B-cell lymphoma1 recruiting
- Gastric and oesophageal cancer1 recruiting
- Lung cancer1 recruiting
- Multiple myeloma1 recruiting
- Prostate cancer1 recruiting
Closed trials
Recruiting
Completed
Completed
Completed
Completed
Completed
Site data: ClinicalTrials.govUpdated 18 Nov 2026